Effects of immunosuppressants on receptor activator of NF-κB ligand and osteoprotegerin production by human osteoblastic and coronary artery smooth muscle cells

Biochemical and Biophysical Research Communications

Volumn 280, Issue 1, 2001, Pages 334-339

  Hofbauer, Lorenz C ^a,d   Shui, Chaoxiang ^a   Riggs, B Lawrence ^a   Dunstan, Colin R ^c   Spelsberg, Thomas C ^b   O'Brien, Timothy ^a   Khosla, Sundeep ^a  

^a MAYO CLINIC   (United States)

^b MAYO GRADUATE SCHOOL   (United States)

^c AMGEN INC   (United States)

^d PHILIPPS UNIVERSITY MARBURG   (Germany)

Author keywords

Cyclosporine A; Osteoblasts; Osteoprotegerin; Rapamycin; Smooth muscle cell; Stromal cell

Indexed keywords

CYCLOSPORIN A; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; LIGAND; MESSENGER RNA; OSTEOCLAST DIFFERENTIATION FACTOR; OSTEOPROTEGERIN; RAPAMYCIN; TACROLIMUS;

ARTERY CALCIFICATION; ARTICLE; BONE ATROPHY; CELL FUNCTION; CELL PROLIFERATION; CONTROLLED STUDY; CORONARY ARTERY; HUMAN; HUMAN CELL; IMMUNOSUPPRESSIVE TREATMENT; ORGAN TRANSPLANTATION; OSTEOBLAST; OSTEOCLAST; OSTEOPOROSIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; SMOOTH MUSCLE FIBER; STROMA CELL; VASCULAR DISEASE;

EID: 0034817070     PISSN: 0006291X     EISSN: None     Source Type: Journal    
DOI: 10.1006/bbrc.2000.4130     Document Type: Article

References (32)

1. New issues in therapy after renal transplantation
2. Post-transplantation bone disease: The role of immunosuppressive agents and the skeleton
3. Tacrolimus
4. The deleterious effects of long-term cyclosporine A, cyclosporine G, and FK-506 on bone mineral metabolism in vivo
5. Rapamycin: A bone sparing immunosuppressant?
6. Lack of change of cancellous bone volume with short-term use of the new immunosuppressant rapamycin in rats
7. Cyclosporine A, but not FK506, selectively induces renal and coronary artery smooth muscle contraction
8. Rapamycin inhibits transplant vasculopathy in long-surviving rat heart allografts
9. Cyclosporin A in the oophorectomized rat: Unexpected severe bone resorption
10. Cyclosporine friend or foe?
11. Cyclosporine A stimulates proliferation of vascular smooth muscle cells and enhances monocyte adhesion to vascular smooth muscle cells
12. Osteoprotegerin (OPG) ligand is a cytokine that regulates osteoclast differentiation and activation
13. A homologue of the TNF receptor and its ligand enhance T-cell growth and dendritic-cell function
14. OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph-node organogenesis
15. Evidence for a role of a tumor necrosis factor-α (TNF-α)-converting enzyme-like protease in shedding of TRANCE, a TNF family member involved in osteoclastogenesis and dendritic cell survival
16. Activated T cells regulate bone loss and joint destruction in adjuvant arthritis through osteoprotegerin ligand
17. Osteoprotegerin ligand: A regulator of immune responses and bone physiology
18. Osteoprotegerin: A novel secreted protein involved in the regulation of bone density
19. Osteoprotegerin-deficient mice develop early onset osteoporosis and arterial calcification
20. Stimulation of osteoprotegerin ligand and inhibition of osteoprotegerin production by glucocorticoids in human osteoblastic lineage cells: Potential paracrine mechanisms of glucocorticoid-induced osteoporosis
21. Development and characterization of conditionally immortalized osteoblast precursor cell lines from human bone marrow stroma
22. Development and characterization of a conditionally immortalized human fetal osteoblastic cell line
23. Osteoprotegerin production by human osteoblast lineage cells is stimulated by vitamin D, bone morphogenetic protein-2, and cytokines
24. Modulation of osteoclast differentiation and function by the new members of the tumor necrosis factor receptor and ligand families
25. Bone resorption by osteoclasts
26. Osteoblastic differentiation is enhanced by rapamycin in rat osteoblastic-like osteosarcoma (ROS 17/28) cells
27. Rapamycin inhibits clonal expansion and adipogenic differentiation of 3T3-L1 cells
28. The expression of osteoprotegerin and RANK ligand and the support of osteoclast formation by stromal-osteoblast lineage cells is developmentally regulated
29. Osteoprotegerin reverses osteoporosis by inhibiting endosteal osteoclasts and prevents vascular calcification by blocking a process resembling osteoclastogenesis
30. Effect of cyclosporine A on normal human osteoblasts in vitro
31. Vascular effects of cyclosporine A in vivo and in vitro
32. Atherogenic effects of cyclosporine in an experimental model of arterial autograft